Plain-English translation of NCT07188103 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two treatments for people with advanced esophageal squamous cell carcinoma whose first round of treatment didn't work. The first treatment is a focused radiation therapy given over just one week, and the second is a newer immunotherapy medication called ivonescimab. The goal is to see if using these two treatments together can help slow or stop the cancer from growing while being safe for patients to tolerate.
When esophageal cancer comes back or doesn't respond to initial treatment, doctors still don't have a clear best option for second-line therapy. This medication represents a new approach using the immune system to fight cancer, and researchers want to see if combining it with targeted radiation could be more effective than either treatment alone.
You likely qualify if…
You likely don't qualify if…
You would first receive focused radiation therapy delivered over 5 treatments in one week, targeting your cancer. Then, within a week after finishing radiation, you would begin receiving the immunotherapy medication as an injection every three weeks. You would continue this medication until your cancer progresses, you experience side effects you can't tolerate, or you decide to stop. The study will follow you for about 2 years total, with regular visits to check how you're doing and whether the treatment is working.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China